← Who reports today · Health Care
RVTY · Q2 2026
Archived report (Q2 2026). Latest deep dive →
The quarter in brief
Revenue grew 1.3% y/y to $730M, operating margin 12.2% vs 12.6%, net income $52M (−3.9% y/y).
Net income
$51.8M
down 3.9% y/y
Revenue
$730M
up 1.3% y/y
Operating income from continuing operations
$89.3M
down 1.6% y/y
All figures in $M.
| Line item | Amount and change |
|---|---|
| Revenue | $730 · +1.3% |
| Cost of revenue | $313 · −4.5% |
| Selling, general and administrative expenses | $279 · +12.1% |
| Research and development expenses | $49 · −8.1% |
| Operating income from continuing operations | $89.3 · −1.6% · 12.2% margin |
| Interest income | $5.3 · −37.0% |
| Interest expense | $23 · +0.2% |
| Change in fair value of investments | $5.3 · +169% |
| Other expense, net | $2.8 · −49.6% |
| Income from continuing operations, before income taxes | $63.5 · −7.5% |
| Provision for income taxes | $10.1 · −25.2% · 15.8% effective rate |
| Loss from discontinued operations | $1.7 · +30.4% |
| Net income | $51.8 · −3.9% · $0.48/sh · 7.1% margin |
Verdict: revenue grew 1.3% y/y to $730M, operating margin 12.2% vs 12.6%, net income $52M (−3.9% y/y).
GAAP operating income from continuing operations includes $16 million of tariff related refunds.
Source and notation
Source: Revvity press release, 8-K EX-99.1 of 08/04/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open as an image: RVTY, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “RVTY Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/rvty/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/rvty/q2-2026"><img src="https://whoreportstoday.com/t/rvty/q2-2026/sankey.png" alt="RVTY Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/rvty/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/rvty/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/rvty/q2-2026">RVTY Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Pro forma revenue was $711 million, up 4%, and pro forma organic revenue grew 3%.
- Operating income was $89M, a 12.2% margin vs 12.6% a year earlier.
- The effective tax rate was 15.8% vs 19.6% a year earlier.
- Diluted EPS was $0.48 vs $0.47 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
RVTY — a health science company that sells instruments, reagents, software and services for drug discovery and life science research, and diagnostic tests for newborn and reproductive health, immunodiagnostics and other clinical labs.
It earns money in two segments: Life Sciences, serving pharmaceutical, biotech and academic researchers, and Diagnostics, serving clinical and public health laboratories. · Source: annual report (Form 10-K, SEC)
More reports: SOLV · Q2 2026 · STE · Q1 FY2027 · SYK · Q3 2026 · TECH · Q4 FY2026 · TMO · Q3 2026 · UHS · Q3 2026 · UNH · Q3 2026 · VEEV · Q2 FY2027 · VRTX · Q3 2026 · VTRS · Q2 2026 · all reports